LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp.

Vaccine

Volumn 16, Issue 7, 1998, Pages 732-740

  Chong, Celeste ^a   Friberg, Maria ^a   Clements, John D ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Enterotoxins; Mucosal adjuvants; Mucosal immunity; Oral vaccines

Indexed keywords

ESCHERICHIA COLI ENTEROTOXIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 2; MUTANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; HOST RESISTANCE; IMMUNIZATION; IMMUNOSTIMULATION; INFECTION RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; SALMONELLA;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; BACTERIAL TOXINS; CYTOKINES; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FECES; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; LYMPH NODES; MICE; MICE, INBRED BALB C; MUTATION; NEUTRALIZATION TESTS; SALMONELLA INFECTIONS, ANIMAL; SPLEEN;

EID: 0032054708     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00255-7     Document Type: Article

References (32)

1. 1 Cebra, J.J., Fuhrman, J.A., Lebman, D.A. and London, S.D., Effective gut mucosal stimulation of IgA-committed B cells by antigen. In: Vaccines 86: New Approaches to Immunization. Developing Vaccines Against Parasitic, Bacterial, and Viral Diseases (Eds Brown, F., Channok, R.M. and LErner, R.A.). Cold Spring Harbor Laboratory, New York, 1986, pp. 129-133.
2. 2 Apter F.M., Michetti, P., Winner II, L.S., Mack, J.A., Mekalanos, J.J. and Neutra, M.M. Analysis of the roles of anti-lipopolysaccharide and anti-cholera toxin immunoglobin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo. Infect. Immun. 1993, 61, 5279-5285.
3. 3 Clemens, J.D., Sack, D.A. and Harris, J.R. et al. Cross protection by B subunit-whole cell cholera vaccine against diarrhea asociated with heat-labile toxin-producing enterotoxigenic Escherichia coli: Results of a large-scale field trial. J. Infect. Dis. 1988, 158, 372-377.
4. 4 Lamm, M.E., Nedrud, J.G., Kaetzel, C.S. and Mazanec, M.B., New insights into epithetial cell function in mucosal immunity: neutralization of intacellular pathogens and excretion of antigens by IgA. In: Essentials of Mucosal Immunology (Eds Kagnoff, M.F. and Kiyono, H.). Academic Press, New York, 1996.
5. 5 Michetti, P., Mahan, M.J., Slauch, J.M., Mekalanos, J.J. and Neutra, M.R. Monoclonal secretory IgA protects mice against oral challenge with the invasive pathogen Salmonella typhimurium. Infect. Immun. 1992, 60, 1786-1792.
6. 6 Clements, J.D., Hartzog, N.M. and Lyon, F.L. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 1988, 6, 269-277.
7. 7 Elson, C.O. Cholera toxin and its subunits as potential oral adjuvants. Immunol. Today, 1989, 14, 29-33.
8. 8 Lycke, N., Tsuji, T. and Holmgren, J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 1992, 22, 2277-2281.
9. 9 Xu-Amano, J., Kiyono, H. and Jackson, R.J. et al. Helper T cell subsets for immunoglobin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosal associated tissues. J. Exp/ Med. 1993, 178, 1309-1320.
10. 10 Yamamoto, M., Vancott, J.L. and Okahashi, N. et al. The role of Th1 and Th2 cells for mucosal IgA responses. Ann N.Y. Acad. Sci., 1996, 778, 64-71.
11. 11 Dickinson, B.L. and Clements, J.D. Dissociation of Escherichia coli heat labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 1995, 63, 1617-1623.
12. 12 Pizza, M., Domenighini, M., Hol, W. et al. Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol. Microbiol. 1994, 14, 51-60.
13. 13 Tsuji, T., Yokochi, T., Kamiya, H., Kawamoto, Y., Miyama, A. and Asano, Y. Relationship between a low toxicity of the mutant A subunit of enterotoxigenic Esherichia coli enterotoxin and its strong adjuvant action. Immunol. 1997, 90, 176-182.
14. 14 Yamamoto, S., Takeda, Y. and Yamamoto, M. et al. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 1997, 185, 1203-1210.
15. 15 Yamamoto, S., Kiyono, H. and Yamamoto, M. et al. A nontoxic mutant of cholera elicits Th-2 type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. 1997, 94, 5267-5272.
16. 16 Dickinson, B.L. and Clements, J.D., Use of Escherichia coli heat-labile enterotoxin as an oral adjuvant. In: Mucosal Vaccines (Eds Kiyono, H., Ogra, P.L. and McGhee, J.R.). Academic Press, New York, 1996, pp. 73-87.
17. 17 Katz, J.M., Lu, X., Galphin, J.C. and Clements, J.D., Heat-labile enterotoxin from Escherichia coli as an adjuvant for oral influenza vaccination. In: Options for the Control of Influenza III (Eds Brown, L.E., Hampson, A.W. and Webster, R.G.). Elsevier Science, New York, 1996, pp. 292-297
18. 18 Cardenas, L. and Clements, J.D. Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin. Microbiol. Rev. 1992, 5, 328-342.
19. 19 Cardenas, L., Dasgupta, U. and Clements, J.D. Influemce of strain viability and antigen dose on the use of attenuated mutants of Salmonella as vaccine carriers. Vaccine, 1994, 12, 833-840.
20. 20 Smith, B.P., Reina-Guerra, M., Stocker, B.A.D., Hoiseth, S.K. and Johnson, E. Aromatic-dependent Salmonella dublin as a parental modified live vaccine for calves. Am. J. Vet. Res. 1984, 45, 2231-2235.
21. 21 Bao, J.X. and Clements, J.D. Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers. Am. J. Vet. Res. 1984, 45, 2231-2235.
22. 22 Chong, C., Bost, K.L. and Clements, J.D. Differential production of Interleukin-12 mRNA by murine macrophanges in response to viable or killed Salmonella spp.. Infect. Immun. 1991, 59, 3841-3845.
23. 23 Xu-Amano, J., Jackson, R.J., Fujihashi, K., Kiyono, H., Staats, H.F. and McGhee, J.R. Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine 1994, 23, 903-911.
24. 24 Hashigucci, K., Ogawa, H. and Ishidate, T. et al. Antibody response in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine, 1996, 14, 113-119.
25. 25 Katz, J., Lu, X., Young, S.A. and Galphin, G.C. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J. Infect. Dis. 1997, 175, 352-363.
26. 26 Lee, C.K., Weltzin, R. and Thomas, W.D. et al. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J. Infect. Dis. 1995, 172, 161-171.
27. 27 Weltzin, R., Kleanthous, H., Guirakhoo, F., Monath, T.P. and Lee, C.K. Novel intanasal immunization techniques fro antibody induction and protection of mice against Helicobacter felis infection. Vaccine 1997, 4, 370-376.
28. 28 Wu, Y.-Y., Nahm, M.H., Guo, Y., Russell, M.W. and Briles, D.E. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J. Infect. Dis. 1997, 175, 839-846.
29. 29 Mason, H.S., Ball, J.M., Shi, J.-J., Jiang, X., Estes, M.K. and Arntzen, D.J. Expression of Norwalk virus capsid protein in transgenic tobacco and potato plants and its oral immunogenicity in mice. Proc. Natl. Acad. Sci. 1996, 93, 5335-5340.
30. 30 Hathaway, L.J., Partidos, C.D., Vohra, P. and Steward, M.W. Induction of systemic immune responses to measles virus synthetic peptides administered intranasally. Vaccine 1995, 13, 1495-1500.
31. 31 Staats, H.F., Nichols, W.G. and Palker, T.J. Systemic and vaginal antibody responses after intranasal immunization with HIV-1 C4/V3 peptide TISP10 MN(A). J. Immunol. 1996, 157, 462-472.
32. 32 Levine, M.M., Kaper, J.B., Black, R.E. and Clements, M.L. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 1983, 47, 510-550.